Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0019829 (Hodgkin's disease)
 30,247 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Five cases of nodular, lymphocyte predominant Hodgkin's disease (nLP HD), in which an association with (n = 3) and transformation to (n = 2) large cell lymphoma (LCL) were found, were studied with monoclonal antibodies against B-, T-, and Reed-Sternberg (R-S) cell-associated antigens and epithelial membrane antigen (EMA) on paraffin sections. Both lymphocytic (L) and histiocytic (H) cells of nLP HD and lymphoma cells of LCL expressed multiple B-cell-associated antigens (detected by LN-1/CDw75, L26, MB2, DBB.42, DBA.44, DND.53, DNA.7 antibodies) but did not react with antibodies against T-cell-associated (MT1, UCHL1/CD45RO) (one exception for CD45RO in LCL) and R-S cell-associated (Leu-M1/CD15, Ber-H2/CD30) antigens. EMA was expressed by L and H cells in all cases and conserved in LCL cells, emphasizing the frequent expression of EMA by the diagnostic cells of nLP HD. An antibody (BNH9) against blood group-related antigens (H and Y oligosaccharide antigens) that does not normally react with lymphoid cells was found to be reactive with few L and H cells in two of five and most LCL cells in four of five cases. The finding might be indicative of abnormal activation of lymphoid cells. The data reinforce current implications that nLP HD is a B-cell malignancy in evolution and that it is not truly representative of Hodgkin's disease in terms of biological and clinical behavior.
 ...
PMID:Further phenotypic evidence that nodular, lymphocyte-predominant Hodgkin's disease is a large B-cell lymphoma in evolution. 224 Mar 55

A new B-lymphoma cell line (DEAU-cell line) was established from a diffuse large-cell lymphoma (centroblastic type) and was successfully grafted in athymic nude mice. Monoclonal antibodies (MoAbs) were generated using splenocytes of DEAU-tumor bearing mice. Before the fusion experiments, cellular immunity of the mice bearing growing DEAU tumors was restored by injection of spleen cells from conventional Balb/C mice. Spleen cells from conventional Balb/C mice immunized with DEAU-cell line were also used for the generation of MoAbs. Four MoAbs (DBB.42 and DBA.44 from normal Balb/C mice, and DNA.7 and DND.53 from athymic nude mice) were investigated because they identified B-cell-associated antigens not destroyed by fixatives. DBB.42 recognized a pan-B cell-associated antigen (molecular weight (mol wt) = 45 Kd). DBA.44 detected a B-cell antigen (mol wt not determined) expressed on a subpopulation of B lymphocytes in the mantle zone of lymphoid follicles. DNA.7 also defined a B-cell antigen (43 Kd) mainly expressed on germinal center cells. Similarly, DND.53 recognized a B-cell antigen (two bands of mol wt 20 Kd and 35 Kd, respectively) mainly expressed on germinal center cells and mantle zone lymphocytes and interdigitating reticulum cells in the paracortical area. Major differences were found in the reactivities of these MoAbs on malignant lymphomas. DBB.42 was positive with almost all B-cell lymphomas and some T-cell lymphomas. Within the group of low-grade B-cell lymphomas, DBA.44 reacted principally with hairy-cell leukemia. DNA.7 reacted mainly with high-grade B-cell lymphomas with a weak positivity in low-grade B-cell lymphomas. DND.53 reacted with all but one B-cell lymphoma, cells of histiocytosis X, and Reed-Sternberg cells. These findings indicate that new MoAbs can be generated by using spleen cells from athymic mice bearing human tumors as well as by new lymphoid cell lines. The MoAbs so generated, as in the present study, are deemed potentially useful for the recognition of B-cell lymphomas in routine diagnostic histopathology. In addition, DND.53 could be of value for the diagnosis of histiocytosis X and the detection of Reed-Sternberg cells in Hodgkin's disease.
 ...
PMID:Production of anti-B monoclonal antibodies (DBB.42, DBA.44, DNA.7, and DND.53) reactive on paraffin-embedded tissues with a new B-lymphoma cell line grafted into athymic nude mice. 267 17

An immunohistochemical study was performed on 132 routinely processed trephine biopsies of the bone marrow (40 reactive lymphocytosis, 80 B-cell lymphomas, 7 T-cell lymphomas, 5 Hodgkin's diseases), using 4 monoclonal antibodies, DBB.42, DNA.7, DBA.44, DND.53, which are directed against B-lymphocyte associated antigens, not destroyed by fixation. DBB.42, DNA.7 and DBA.44 are formalin and Bouin resistant. They do not stain myeloid, erythroblastic, histiomonocytic and endothelial cells, and are particularly suitable for bone marrow biopsies. DBB.42 and DNA.7 in association, identify all B-cell lymphomas and no T-cell lymphoma. DBB.42 recognizes respectively 65/65 and 13/15 low and high grade malignancy B-cell lymphomas, and DNA.7, 54/65 and 15/15. In our hands, these 2 antibodies are more reliable than L26 and MB2 on bone marrow biopsies. DBA.44 identifies 15/15 hairy-cell leukemias, and interestingly stains only 10% of other B-cell lymphomas, and no T-cell lymphoma. DND.53 is less specific, but reveals Reed-Sternberg cells. Combined immunostaining with anti T-lymphocyte antibody CD3, let us appreciate the contribution and the limits of immunohistochemistry in the diagnosis of bone marrow lymphoproliferative diseases, especially for interstitial and nodular lymphoid infiltrates of undetermined significance. These results point out the value of these 4 monoclonal antibodies in routinely processed bone marrow biopsies, particularly of DBB.42 and DBA.44.
 ...
PMID:[Immunophenotyping of B lymphoma in bone marrow biopsies. Contribution of 4 monoclonal antibodies used on paraffin-embedded tissues:DDB.42,DNA.7,DNA.44 and DND.53]. 839 39